Published on
August 5, 2019
- 06:00 GMT
Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD
LONDON, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler (“DPI”) formulation of its lead …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Media, Advertising & PR
...
